Drug Repurposing of Octreotide as a Selective Apelin Receptor Antagonist Against Pathological Angiogenesis: Integrated Virtual Screening and Zebrafish Validation.

Purpose: The apelin/APJ system represents a promising VEGF-independent therapeutic target for treating retinopathy of prematurity (ROP), given its selective upregulation in pathological retinal neovasculature. We aimed to identify clinically translat…

Preview only. Read the full abstract at the source